# To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients

> **NCT04761731** · PHASE4 · COMPLETED · sponsor: **Linical Korea** · enrollment: 31 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** ADVAGRAF®

## Key facts

- **NCT ID:** NCT04761731
- **Lead sponsor:** Linical Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-12-14
- **Final completion:** 2017-12-14
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-02-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04761731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04761731, "To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04761731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*